Biogen and Eisai say Alzheimer’s treatment slowed disease progression, backing amyloid plaque theory
July 25, 2018 at 16:25 PM EDT
The drug, dubbed BAN2401, slowed declines associated with Alzheimer’s disease by 30 percent at its highest dose in the trial, compared with placebo, after 18 months.